Cullinan Therapeutics, Inc. (CGEM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.09-0.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CGEM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -40.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CGEM — earnings miss
Dated 2026-08-06
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Progress in CLN-978 trials is key to Cullinan's future. Positive results could boost confidence.
Supportive ifPositive data from the Phase 1 OUTRACE trials for CLN-978 shared in upcoming updates.
Worry ifNegative data or delays in the Phase 1 OUTRACE trials for CLN-978.
Why it matters: Extending the cash runway is crucial for funding ongoing trials and operations.
Supportive ifManagement says they have a successful funding round. This will extend cash runway into 2029.
Worry ifManagement says cash runway is shorter than expected. They face funding challenges.
Why it matters: Litigation can affect trials and the company's reputation. This can impact stock prices.
Worry ifLitigation ends in the company's favor or does not affect clinical trials.
Less concerning ifBad news in lawsuits can slow down trials. It may also lead to fines.
Why it matters: This data will show how well velinotamig works for autoimmune diseases. Good results could help its development.
Supportive ifMulti-dose data for velinotamig shows strong clinical activity. It is safe for SLE patients.
Worry ifData shows no strong clinical activity for velinotamig in SLE patients. There are no safety issues.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$169 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $595 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,670 loss on $10,000 · 26.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates will provide insights into the effectiveness of CLN-978 in SLE patients. This could influence treatment strategies.
Supportive ifManagement reports good clinical results from the OUTRACE SLE trial.
Worry ifUpdates show no better clinical results or safety for CLN-978 in SLE.
Why it matters: The results of lawsuits could affect financial health and focus on operations.
Worry ifNo new lawsuits or a good ruling in current cases.
Less concerning ifNew lawsuits filed or bad results in current cases.
Why it matters: Earnings reports can impact stock performance. Positive results may reflect strong progress in clinical trials and cash management.
Watch forEarnings report shows revenue growth and good updates on clinical trials.
Also watch forEarnings report shows losses or delays in clinical programs.
Why it matters: Progress in these trials is key for the company's future. Positive results can boost investor confidence.
Supportive ifPositive Phase 1 trial results for CLN-978 in hard-to-treat RA or SLE.
Worry ifNegative trial results or delays in the clinical trial schedule.
Why it matters: This data will help check how well CLN-978 works for systemic lupus erythematosus. Good results could boost its market potential.
Supportive ifCLN-978 shows promising early data in SLE patients. This may lead to more development.
Worry ifQ4 data shows no major effectiveness for CLN-978 in SLE patients.
Why it matters: This data will show if CLN-978 can treat rheumatoid arthritis. Good results can help further development.
Supportive ifCLN-978 shows strong clinical remissions in RA patients. Data will be shared in Q3 2026.
Worry ifMulti-dose data shows no improvement in RA patients treated with CLN-978.
Why it matters: This study will test a new treatment for acute myeloid leukemia. Positive results could lead to regulatory approval.
Supportive ifCLN-049 Phase 2 study begins in Q3 2026, showing progress in AML treatment.
Worry ifPhase 2 study is delayed or does not start as planned.